Skip to content
Biodatica
Start free

Bio-Thera Solutions

Wuhan, Hubei

OncologyPhase III
Compare Sign in to watch

What changed

Phase I trial registered: A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants

2d agoTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

80no change

Momentum 80 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

471 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Dec 25, 2025

    Lung Cancer (NSCLC), EGFR Activating Mutation, Adenocarcinoma Lung, Postoperative Adjuvant Therapy · NOT_YET_RECRUITING · sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data

    ClinicalTrials.gov · NCT07287904 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Oct 14, 2025

    Carcinoma, Non-Small-Cell Lung · RECRUITING · sponsor: Bio-Thera Solutions · A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants

    ClinicalTrials.gov · NCT07180862 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Jul 19, 2024

    Carcinoma, Non-Small-Cell Lung · TERMINATED · sponsor: Bio-Thera Solutions · A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC

    ClinicalTrials.gov · NCT06280196 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources